Evidence map›Paper›PMID 27652094›Full record

ArticleSpringerPlus2016

CRISPR-Cas9 directed knock-out of a constitutively expressed gene using lance array nanoinjection.

John W Sessions, Craig S Skousen, Kevin D Price, Brad W Hanks, Sandra Hope, Jonathan K Alder, Brian D Jensen

Abstract read
In one paragraph

Article in SpringerPlus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Optimization of CRISPR-Cas system for clinical cancer therapy.Bioengineering & translational medicine · 2023
    Review
  3. Review
  4. CRISPR/Cas systems: Delivery and application in gene therapy.Frontiers in bioengineering and biotechnology · 2022
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

John W SessionsDepartment of Mechanical Engineering, Brigham Young University, Provo, UT USA.
Craig S SkousenDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT USA.
Kevin D PriceDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT USA.
Brad W HanksDepartment of Mechanical Engineering, Brigham Young University, Provo, UT USA.
Sandra HopeDepartment of Microbiology and Molecular Biology, Brigham Young University, Provo, UT USA.ORCID 0000-0002-9060-0485
Jonathan K AlderDepartment of Physiology and Developmental Biology, Brigham Young University, Provo, UT USA.
Brian D JensenDepartment of Mechanical Engineering, Brigham Young University, Provo, UT USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCRISPR-Cas9 genome editing and labeling has emerged as an important tool in biologic research, particularly in regards to potential transgenic and gene therapy applications. Delivery of CRISPR-Cas9 plasmids to target cells is typically done by non-viral methods (chemical, physical, and/or electrical), which are limited by low transfection efficiencies or with viral vectors, which are limited by safety and restricted volume size. In this work, a non-viral transfection technology, named lance array nanoinjection (LAN), utilizes a microfabricated silicon chip to physically and electrically deliver genetic material to large numbers of target cells. To demonstrate its utility, we used the CRISPR-Cas9 system to edit the genome of isogenic cells. Two variables related to the LAN process were tested which include the magnitude of current used during plasmid attraction to the silicon lance array (1.5, 4.5, or 6.0 mA) and the number of times cells were injected (one or three times).

resultsResults indicate that most successful genome editing occurred after injecting three times at a current control setting of 4.5 mA, reaching a median level of 93.77 % modification. Furthermore, we found that genome editing using LAN follows a non-linear injection-dose response, meaning samples injected three times had modification rates as high as nearly 12 times analogously treated single injected samples.

conclusionsThese findings demonstrate the LAN's ability to deliver genetic material to cells and indicate that successful alteration of the genome is influenced by a serial injection method as well as the electrical current settings.

Indexed as

CRISPR-Cas9Current controlGene knock-outLance array nanoinjectionNon-viral transfectionSerial injection

Identifiers

PMID27652094
PMCPMC5017990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.